Related Experiment Video
Updated: Jul 19, 2025

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 1, 2011
Deficiency of Interleukin-1 Receptor Antagonist: New Genetic Autoinflammatory Disease as a Diagnostic Challenge for
Andrea Rivera-Sepulveda1,2, Francisco Colón-Fontánez2, Maricarmen López2,3
1Department of Pediatrics, Division of Emergency Medicine, Nemours Children's Hospital, Orlando, Florida, United States.
Insights
Early diagnosis of interleukin-1 receptor antagonist deficiency, a rare autoinflammatory disease, is crucial. Prompt anakinra treatment can lead to remission in infants with severe systemic inflammation, skin, and bone issues.
Area of Science:
- Pediatric Rheumatology
- Autoinflammatory Diseases
- Genetics
Background:
- Interleukin-1 receptor antagonist (IL-1RA) deficiency is a rare, early-onset autoinflammatory disease.
- Clinical manifestations include systemic inflammation, skin lesions, and bone involvement.
- Diagnosis can be delayed due to non-specific symptoms and resistance to conventional therapies.
Purpose of the Study:
- To report a case of a very young infant with IL-1RA deficiency.
- To highlight the importance of early empirical treatment with anakinra.
- To emphasize the need for prompt recognition and management of this rare condition.
Main Methods:
- Case presentation of a 5-month-old boy with severe inflammatory symptoms.
- Diagnostic workup including skin biopsy and bone scan.
- Empirical treatment with anakinra initiated prior to genetic confirmation.
Main Results:
- The patient presented with pustular eruption, cellulitis, and osteomyelitis, unresponsive to antibiotics and steroids.
- Skin biopsy showed psoriasiform dermatitis; bone scan revealed multifocal osteomyelitis.
- Anakinra administration led to clinical improvement within 72 hours.
Conclusions:
- This case represents one of the youngest patients treated empirically with anakinra for suspected IL-1RA deficiency.
- Early recognition of clinical signs and consideration of IL-1RA deficiency in the differential diagnosis are critical.
- Prompt treatment with anakinra can significantly reduce morbidity and mortality associated with this rare genetic disease.
Abstract:
Deficiency of interleukin-1 receptor antagonist is a rare autoinflammatory disease that affects infants early in life. It often presents with systemic inflammation, skin and bone involvement. We present a 5-month-old boy who was hospitalized due to generalized erythematous pustular eruption with secondary impetigo, cellulitis, bronchiolitis, and elevated inflammatory markers. The patient was unresponsive to multiple courses of intravenous antibiotics, systemic, and topical steroid medications. The patient was evaluated by dermatology and rheumatology services among other subspecialities. Skin biopsy showed changes consistent with psoriasiform dermatitis, while bone scans showed multifocal osteomyelitis. The patient was started empirically on anakinra with improvement at 72 hours upon administration. This is one of the youngest reported case in the literature to be started on anakinra empirically prior to genetic confirmation of the mutation. A comprehensive literature review revealed that approximately 20 genetically confirmed patients, including our patient, have been reported with this genetic disease. It is imperative to recognize this disease early to achieve adequate response and remission. Therefore, clinical symptoms and the associated differential diagnosis for this disease should be constantly reassessed and reviewed by pediatricians and subspecialists to detect the disease as early as possible and reduce the high morbidity and mortality associated with delayed diagnosis and treatment.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The JAK-STAT Signaling Pathway
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Rheumatic Heart Disease I: Introduction

